Investigators reported in a bioRxiv preprint that the creatine transporter SLC6A8 represents a metabolic vulnerability in acute myeloid leukemia (AML). The title states this vulnerability is specifically “immune pressure-exposed,” which indicates the authors linked transporter activity or expression to selective pressures exerted by the immune environment. The work appears framed as an identification of a non-genetic, metabolic dependency in AML rather than a canonical oncogenic driver.
The preprint format signals these are preliminary findings. The authors expressed their results in a manuscript posted publicly on bioRxiv; however, the supplied excerpt did not include the core experimental data, figures, or numerical outcomes. Readers should therefore treat the claim as an initial report pending full peer-reviewed publication and access to the full methods and results.
The preprint lists Petya Apostolova as first author and includes a multi-institutional team spanning groups at the University of Basel, Johns Hopkins University, Max Planck Institute of Immunobiology and Epigenetics, University Hospital Basel, and other centers. The DOI is provided in the source excerpt and the article is explicitly noted as not peer reviewed. The supplied material contains author names, many affiliations, and institutional links, but the excerpt stopped short of detailed author contributions or expanded acknowledgements.
The public posting on bioRxiv enables early access to hypotheses and initial datasets. At the same time, posting does not substitute for peer review. The study team reported the central assertion in the manuscript title and author list; the excerpt did not include conflict-of-interest statements or funding sources.
The manuscript title—The creatine transporter SLC6A8 is an immune pressure-exposed metabolic vulnerability in acute myeloid leukemia—explicitly ties transporter biology to both metabolism and immune interactions. That phrasing indicates the authors observed a relationship between the creatine transporter SLC6A8 and tumor behavior under immune challenge or selection.
The language used in the title suggests at least two conceptual elements in the reported work: (1) SLC6A8 participates in a metabolic pathway that AML cells rely on; and (2) the dependency becomes apparent or is modulated under immune pressure. Because the excerpt did not include experimental descriptions, investigators’ precise definitions of “immune pressure,” the models used to impose it, and how SLC6A8 function changed under those conditions were not available in the provided text.
The supplied source excerpt included author names, affiliations and the DOI, but did not contain the body of the manuscript where experiments, results, and statistics are typically reported. The excerpt did not provide:
Because those elements were not present in the supplied text, this rewrite does not extrapolate or infer experimental details. The study team reported the central finding in the title, but the full manuscript must be consulted to evaluate experimental rigor and reproducibility.
The title and author list raise multiple specific questions that remain unanswered in the excerpted material and that will determine translational relevance. Chief among them:
The supplied source excerpt did not present answers to these points. Investigators reported the central claim, but full assessment requires the complete manuscript and subsequent peer review.
If readers wish to evaluate the evidence themselves, the next step is to consult the full preprint at the DOI provided in the source excerpt and to watch for peer-reviewed follow-up. The manuscript, as presented in the excerpt, concludes with an assertion about SLC6A8’s role in AML; it does not include the experimental or clinical detail necessary to adjudicate therapeutic potential or to design immediate clinical tests.